Victoria Whyte - GlaxoSmithKline plc Insider

GlaxoSmithKline plc -- USA Stock  

USD 34.99  0.25  0.71%

Company Secretary

Ms. Victoria L. Whyte is Company Secretary of GlaxoSmithKline PLC., since 1 January 2011. She is a solicitor and a Fellow of the Institute of Chartered Secretaries and Administrators. Victoria was formerly Deputy Secretary and Secretary to the Remuneration Committee. She has acted as Secretary to the Board and all the Boards Committees since her appointment as Company Secretary on 1 January 2011.
  Executive Since 2011      
(44) 20 8047 7807  www.gsk.com

Management Efficiency

The company has Return on Asset of 6.7 % which means that on every $100 spent on asset it made $6.7 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 64.55 % implying that it generated $64.55 on every 100 dollars invested.
The company has 25.35 B in debt with debt to equity (D/E) ratio of 394.1 . This implies that the company may be unable to create cash to meet all of its financial commitments. GlaxoSmithKline plc has Current Ratio of 0.63 suggesting that it has not enough short term capital to pay financial commitments when the payables are due.

Similar Executives

Entity Summary

GlaxoSmithKline plc creates, discovers, develops, manufactures, and markets pharmaceutical products, including vaccines, overthecounter medicines, and healthrelated consumer solutions worldwide. GlaxoSmithKline plc (GSK) is traded on New York Stock Exchange in USA. It is located in UNITED KINGDOM and employs 101,255 people. GlaxoSmithKline plc is listed under Pharmaceutical Products category by Fama And French industry classification.

Did you try this?

Run Portfolio Suggestion Now
   

Portfolio Suggestion

Get suggestions outside of your existing asset allocation including your own model portfolios
Hide  View All  NextLaunch Portfolio Suggestion
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add GlaxoSmithKline plc to your portfolio

Top Management

GlaxoSmithKline plc Leadership Team
Vindi Banga, Director
Lynn Elsenhans, Director
Luke Miels, President
Daniel Podolsky, Director
Emma Walmsley, President
Luc Debruyne, President
Andrew Witty, CEO, MBA
Brian McNamara, CEO, MBA
Roy Anderson, Director
Philip Hampton, Director
Simon Dingemans, Director
Vivienne Cox, Director, Ph.D
Bill Louv, President
Roger Connor, President
Abbas Hussain, President
Phil Thomson, President
Judy Lewent, Director
Hans Wijers, Director
Stephanie Burns, Director, Ph.D
Moncef Slaoui, Chairman, Ph.D
Urs Rohner, Director
Deryck Maughan, Director
Jesse Goodman, Director, Ph.D
Laurie Glimcher, Director
Nick Hirons, President
Victoria Whyte, Executive
Daniel Troy, SVP
Shah Hussain, President
Manvinder Banga, Director
David Redfern, Executive
Patrick Vallance, President
Stacey Cartwright, Director
Claire Thomas, SVP

Stock Performance

GlaxoSmithKline plc Performance Indicators